Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 17Observational 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1SCLC, Extensive Stage 1Melanoma 1Lung Neoplasms 1Liver Diseases 1Esophageal Neoplasms 1Breast Neoplasms 1Advanced Colorectal Carcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 60palbociclib 37Trastuzumab 31Letrozole 26Immunohistochemistry 26Drug Therapy 24Anastrozole 24Radiotherapy 21Gene Expression Profiling 20Amplified Fragment Length Polymorphism Analysis 20Mastectomy, Segmental 19Biopsy 19Tamoxifen 18exemestane 17Interviews as Topic 17ribociclib 16Mastectomy 16Fulvestrant 16Paclitaxel 15Magnetic Resonance Spectroscopy 15Psychiatric Rehabilitation 14High-Energy Shock Waves 14Polymerase Chain Reaction 13Observation 13Microarray Analysis 13Capecitabine 13trastuzumab deruxtecan 12Neoadjuvant Therapy 12Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Breast Neoplasms × toripalimab × Clear all
NCT04234620 2020-01-21

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Shanghai Junshi Bioscience Co., Ltd.

Unknown
800 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡